Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D Supplementation in Vitamin D Deficient Patients Receiving Neoadjuvant Chemotherapy for Operable Triple Negative Breast Cancer
NCT04677816Phase 2Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of vitamin d in triple-negative breast cancer (TNBC) and Vitamin D deficiency (VDD) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Pathologic Complete Response at 22 weeks. Started Oct 2021; status: recruiting.
02
Drugs
vitamin d
03
Conditions
triple-negative breast cancer (TNBC)Vitamin D deficiency (VDD)
Beyond the preview
Go deeper on NCT04677816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677816.